News

• Jyseleca® approved in Japan for ulcerative colitis
  03/28/2022 / 08:01 - GlobeNewswire
•  
• Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
  03/24/2022 / 21:17 - GlobeNewswire
•  
• Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
  03/24/2022 / 21:01 - GlobeNewswire
•  
• Galapagos increases share capital through subscription right exercises
  03/18/2022 / 22:01 - GlobeNewswire
•  
• Galapagos 2021 results set stage for future growth
  02/24/2022 / 22:01 - GlobeNewswire
•  
• Galapagos receives transparency notification from EcoR1 Capital
  02/03/2022 / 22:01 - GlobeNewswire
•  
• Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
  02/02/2022 / 22:01 - GlobeNewswire
•  
• Galapagos creates new subscription right plan
  01/26/2022 / 22:40 - GlobeNewswire
•  
• Galapagos appoints Paul Stoffels as Chief Executive Officer
  01/26/2022 / 22:01 - GlobeNewswire
•  
• Historic Decree Creates a New Marine Reserve – ‘Reserva Marina de Hermandad’– near the Galapagos Islands to Protect a Massive ‘Swimway’ for Threatened Ocean Wildlife
  01/15/2022 / 03:05 - GlobeNewswire
•  
• Galapagos creates new subscription right plan
  01/13/2022 / 22:01 - GlobeNewswire
•  
• Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
  01/06/2022 / 15:30 - GlobeNewswire
•  
• Dow Jones Celebrates 2021 Achievements
  12/30/2021 / 14:00 - GlobeNewswire
•  
• Galapagos increases share capital through subscription right exercises
  12/03/2021 / 22:01 - GlobeNewswire
•  
• Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
  11/22/2021 / 22:01 - GlobeNewswire